Precision oncology biomarkers are important instruments for tailoring most cancers remedy to particular person sufferers, as they supply insights into tumor biology and information the collection of focused therapies. This discipline has witnessed vital developments in recent times, with state-of-the-art applied sciences and rising methods driving progress.
Key applied sciences in precision oncology biomarker analysis embody:
• Subsequent-generation sequencing (NGS) for complete genomic profiling
• Liquid biopsies for real-time monitoring, and
• Proteomics and metabolomics for a deeper understanding of mobile processes
Practical genomics strategies, reminiscent of CRISPR-Cas9 and RNA interference, assist validate biomarkers and determine new therapeutic targets.
As a number one market intelligence agency, BIS Analysis strives to remain on prime of the newest rising developments within the healthcare sector, amongst a number of different trade verticals.
Within the bid to do the identical, BIS is conducting a deep intelligence webinar on the state-of-the-art applied sciences and rising methods used via the precision oncology biomarkers.
Listed here are all the main points:
Webinar Matter: Precision Oncology Biomarkers | State-of-the-Artwork Applied sciences and Rising Methods
Agenda:
The primary agenda of this webinar is to grasp and discover the next:
• Rationalization of the function of biomarkers in personalised most cancers remedy
• Overview of the challenges in biomarker identification and validation
• Overview of one of the best practices for biomarker discovery and validation
• Dialogue of the significance of rigorous research design and statistical evaluation
• Spotlight examples of profitable biomarker identification and validation research
• Overview of latest and rising applied sciences for biomarker discovery, together with genomics, proteomics, and metabolomics
• Dialogue of the benefits and limitations of those applied sciences
• Spotlight examples of how these applied sciences have been used to determine new biomarkers.
• Presentation of case research that illustrate using biomarker identification in precision oncology.
• Dialogue of the influence of biomarker identification on affected person outcomes and personalised remedy plans
• Overview of the long run instructions of biomarker identification for precision oncology
• Dialogue of the potential for combining a number of applied sciences to enhance biomarker identification and validation.
Audio system:
Our eminent panelists for this webinar will probably be:
Shibicharkravarthy Kannan – Shibichakravarthy is a doctor scientist with medical diploma from India and PhD in Biochemistry & Molecular Biology from College of North Dakota, Grand Forks, ND, USA. Dr. Kannan is at the moment the founder and CEO of Oncophenomics which is an AI pushed preclinical drug discovery and growth firm. Previous to this, he labored because the CEO of Theranosis Life Sciences Pvt Ltd in Hyderabad, India, which is a customized medicine-based startup the place he was main the microfluidics lab-on-a-chip product growth crew.
Michael R. Rossi – Michael R. Rossi, PhD, FACMG is the Vice President of Translational Science and Multi-Modal Actual World Proof Options at ConcertAI. Previous to ConcertAI, he was the Division Head of Molecular Oncology for Stable Tumors at Sema4 and likewise held the title of Affiliate Professor within the Division of Genetics & Genomic Sciences on the Icahn Faculty of Medication at Mount Sinai in New York.
Mike has in depth experience in genomics and genetics purposes for medical diagnostics, most cancers analysis, and oncology medical trials, and has authored or co-authored over 65 peer evaluation publications focusing totally on genomic mechanisms that drive human cancers and response to remedy
Akash Mhaskar – Akash Mhaskar is a principal analyst, healthcare, and leads the cell and gene remedy phase at BIS Analysis. He has about eight years of expertise in healthcare market analysis and consulting. He comes with a wealthy expertise in pharma and med-tech area, with specialization in aggressive evaluation, epidemiology modeling, and influence evaluation.
Nitish Singh – Nitish Kumar is the principal advisor throughout the healthcare unit of BIS Analysis. He has a postgraduate diploma in pharmaceutical sciences and over eight years of expertise managing biopharma, life sciences, and biotechnology domains. Nitish has a profitable observe report of consulting Fortune 500 purchasers within the bio-pharmaceuticals and life sciences area. He’s skilled in making ready epidemiological-based information fashions for biopharmaceutical merchandise.
Why do you have to attend the webinar?
Aside from the truth that a number of skilled minds from the healthcare trade will probably be part of this in depth webinar, this will probably be a terrific alternative:
• To grasp the adoption of oncology biomarkers in precision medication.
• To determine the important thing developments within the ‘oncology biomarkers area.
• To discover upcoming applied sciences for biomarkers
• To evaluate the main challenges hindering the adoption of biomarker-based testing.
• To discover market developments in several areas associated to oncology biomarkers.
Timing and Registration:
The webinar goes to happen on seventeenth Could’23 on the following world timings:
• 09:00 A.M. (EST)
• 02:00 P.M. (GMP)
• 06:30 P.M. (IST)
Go to our web site and register for the occasion immediately.
